Carlos A Scrideli


Country: Brazil


  1. Scrideli C, Assumpção J, Ganazza M, Araújo M, Toledo S, Lee M, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica. 2009;94:781-9 pubmed publisher
  2. Darrigo Júnior L, Lira R, Fedatto P, Marco Antonio D, Valera E, Aguiar S, et al. MicroRNA profile of pediatric pilocytic astrocytomas identifies two tumor-specific signatures when compared to non-neoplastic white matter. J Neurooncol. 2018;: pubmed publisher
    ..In summary, our data demonstrate that PA harbors at least two distinct miRNA signatures, including a subgroup of patients with NF1/PA lesions. ..
  3. Baroni M, Marie S, Fedatto P, Andrade A, Suazo V, Cruzeiro G, et al. Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines. J Neurooncol. 2018;139:51-60 pubmed publisher
    ..These results demonstrated that GBM cell lines had distinct responses to GDF15 knockdown, a fact that can be explained by the different molecular profile of pediatric and adult GBM. ..
  4. Sales L, Pezuk J, Borges K, Brassesco M, Scrideli C, Tone L, et al. Anticancer activity of 7-epiclusianone, a benzophenone from Garcinia brasiliensis, in glioblastoma. BMC Complement Altern Med. 2015;15:393 pubmed publisher
    ..The present study demonstrates for the first time the anticancer potential of 7-epiclusianone against glioblastoma cells, thus meriting its further investigation as a potential therapeutic agent. ..
  5. Peixoto Lira R, Fedatto P, Marco Antonio D, Leal L, Martinelli C, de Castro M, et al. IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis. Endocr Relat Cancer. 2016;23:481-93 pubmed publisher
    ..However, in vitro treatments with high concentrations of OSI-906 (>1μM) showed limited reduction of cell viability, suggesting that OSI-906 alone could not be a suitable therapy to abolish carcinoma cell growth. ..
  6. Scrideli C, Cortez M, Yunes J, Queiroz R, Valera E, da Mata J, et al. mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leuk Res. 2010;34:32-7 pubmed publisher
    ..04) and multivariable analysis (P=0.01). Our data address new information in the complex interaction of the migration/adhesion genes and childhood ALL. ..